Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2025Internal Medicine JournalOpen Access

Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAditya TedjaseputraATAmanda TeyANAnastasios Nalpantidis

Discussion

Loading...

Member takes

Overview

Randomized trial assesses efficacy and safety of induction chemotherapy in acute myeloid leukaemia, indicating good outcomes with idarubicin and midostaurin.

Key Points

  • This study aims to evaluate the efficacy and safety of idarubicin-based 7+3 induction chemotherapy for acute myeloid leukaemia (AML) in a real-world setting.
  • Prospective collection of data from patients assessed for front-line AML treatment.
  • Efficacy endpoints included complete remission rates and overall survival, defined according to European LeukaemiaNet guidelines.
  • Analysis was planned after achieving ≥50 inductions over five years.
  • Complete remission rate was 88% (95% CI: 77-95%) with an induction mortality rate of 1.7% (95% CI: 0-9%).
  • Median overall survival was 17.6 months for adverse-risk patients (P = 0.03) compared to non-adverse-risk patients.
  • FLT3-mutated patients had a remission rate of 89% (95% CI: 67%-99%) with 4-year event-free survival and overall survival at 65% and 68%, respectively.

Cite This Study

Tedjaseputra et al. (2025) studied this question.

synapsesocial.com/papers/6a21bde48d200acffec0ae38https://doi.org/10.1111/imj.70010
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?2024 · 7 citations
  2. 2Genomic Classification and Prognosis in Acute Myeloid Leukemia2016 · 4,535 citations
  3. 3Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?2013 · 65 citations
  4. 4Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations2024 · 47 citations
  5. 52021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party2021 · 776 citations